ArticleOncology letters2018
Potential prognostic biomarkers identified by DNA methylation profiling analysis for patients with lung adenocarcinoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Review
- Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Precise Molecular Subtyping Reveals Heterogeneity of Lung Adenocarcinoma Based on DNA Methylation.Current medicinal chemistry · 2025Article
- Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosome DNA Methylation Profile.Cancers · 2024Article
- Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.BMC cancer · 2021Article
- Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.Yonsei medical journal · 2020Article
- miR-140-3p enhances cisplatin sensitivity and attenuates stem cell-like properties through repressing Wnt/β-catenin signaling in lung adenocarcinoma cells.Experimental and therapeutic medicine · 2020Article
- Methylation inCells · 2020Review
- DNA methylation profiling analysis identifies a DNA methylation signature for predicting prognosis and recurrence of lung adenocarcinoma.Oncology letters · 2019Article
- Paralogous HOX13 Genes in Human Cancers.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma is frequently occurring type of lung cancer with high metastatic risk. We performed a DNA methylation profiling analysis to identify possible prognostic markers involved in lung adenocarcinoma. DNA methylation profiling data (GSE66386) were downloaded from the Gene Expression Omnibus (GEO) database. Differentially methylated genes were identified using a limma package. GO enrichment analysis was performed to identify vital functions related to differential gene methylation, and pathway analysis was performed to assess the associations between different proteins with regard to regulation of cell function and metabolism. The screening results showed a total of 112,662 differentially methylated genes in lung adenocarcinoma patients compared with those of the normal controls. These CpGs were involved in 16,705 genes. The skeletal system development (P=9.46E-27) and embryonic organ morphogenesis (P=8.67E-24) were found to be involved in lung adenocarcinoma. The cancer (P=3.64E-07), Rap1 signaling (P=9.21E-05) and calcium signaling (P=9.21E-05) pathways constituted the important pathways associated with lung adenocarcinoma. In conclusion, methylated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.